Colorectal Cancer

The oral nucleoside TAS-102 (Lonsurf) has been approved by the FDA for patients with advanced colorectal cancer (CRC) who are not responding to other treatments.

A novel basket trial has reported results on the treatment of vemurafenib in variety of nonmelanoma cancers with BRAF V600 mutation.

Eric Van Cutsem, MD, PhD, discusses regorafenib for the treatment of patients with chemorefractory metastatic colorectal cancer (mCRC).

Sonidegib (Odomzo) was approved by the EC for the treatment of patients who have locally advanced basal cell carcinoma (laBCC) and are not amenable to curative surgery or radiation therapy.

The University of Texas MD Anderson Cancer Center in Houston has been selected as the site for one of two new Genome Characterization Centers (GCCs) funded by the National Cancer Institute (NCI) and National Institute of Health (HHSN261200800001E).

Dirk Arnold, MD, director of the Department of Medical Oncology at Klinik für Tumorbiologie, Freiburg, Germany, discusses the advantages of using yttrium-90 (Y-90) as the first line treatment for patients with liver metastases from metastatic colorectal cancer (mCRC).

A study including the largest reported US cohort of patients under age 35 with colorectal cancer (CRC) has discovered that one-third of these patients suffer from hereditary forms of the disease.

S. Yousuf Zafar, MD, Associate Professor of Medicine at Duke Cancer Institute, discusses the association of obesity with metastatic colorectal cancer.

James J. Lee, MD, PhD, assistant professor of medicine, Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, discusses the importance of mismatched repair testing in colorectal cancer (CRC).

According to findings from a phase II study released by Amgen, monotherapy with blinatumomab (Blincyto) showed promising complete remission (CR) or CR with partial hematological recovery (CRh) rates in adult patients with relapsed or refractory Philadelphia chromosome-positive (Ph+) B cell precursor acute lymphoblastic leukemia (ALL).

One gene can encode more than one protein; however, proteins are dynamic (binding to membranes, other proteins, synthesis, degradation), undergo co- and post-translational modification, and exist in a wide range of concentrations in the body.

Metastatic Colorectal Cancer